Key result
This review summarizes recent evidence on inherited channelopathies causing sudden cardiac death in children, including diagnostic criteria, risk stratification, and genotype-specific therapies.
This review provides pediatricians with updated information on the diagnosis, risk stratification, and management of inherited arrhythmogenic diseases causing sudden cardiac death in children.
Offers updated pediatric risk stratification for channelopathies; leaves open need for prospective validation of genotype-specific therapies.
PURPOSE OF REVIEW: In this chapter we will discuss the most recent and relevant evidences published in the field of inherited arrhythmogenic disorders, focusing on the so called 'channelopathies' that are associated with sudden cardiac death (SCD) in children: long QT syndrome (LQTS), short QT syndrome (SQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular tachycardia (CPVT). RECENT FINDINGS: We will discuss the latest diagnostic criteria for channelopathies released by the European Society of Cardiology, the new data on BrS in children and the recent evidence supporting a genotype-specific therapy for LQTS type 3. Moreover, we will present further insights into the risk stratification of the children affected by LQTS, analyzing the role of imaging for the prediction of life-threatening arrhythmias. In addition, we will offer a perspective on how to deal with genetic results in families affected by SCD at very young ages. SUMMARY: The selected publications will aid pediatricians in their clinical work when managing little patients with inherited arrhythmias, providing the most recent information for diagnosis, risk stratification, and management.
No takes yet. Share an insight, caveat, or question.
Vacanti et al. (2017) conducted a review in Inherited arrhythmogenic diseases associated with sudden cardiac death in children. This review summarizes recent evidence on inherited channelopathies causing sudden cardiac death in children, including diagnostic criteria, risk stratification, and genotype-specific therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: